D3 Bio (wuxi) Co., Ltd

This early-phase trial tests an experimental drug called D3S-002, taken as a daily pill, in adults with advanced solid tumors that have MAPK pathway mutations. The study has two parts: first, finding a safe dose, and second, testing that dose alone or with another drug (D3S-001) …

This early-stage trial is testing an experimental oral drug called D3S-003 in 42 people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Particip…

This early-phase trial is testing a new drug called D3L-001 in 128 people with advanced HER2-positive solid tumors. The main goals are to check the drug's safety, find the right dose, and see early signs of whether it can shrink tumors. Participants receive D3L-001 through an IV,…

This study tests a new oral drug called D3S-001, alone or with other cancer drugs, in people with advanced solid tumors that have a specific KRAS G12C mutation. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 442 participants will …